2022年肿瘤免疫研究热点回眸  

Hotspots of cancer immunology in 2022: A review

作　　者：黄波[1] 张毅[2] HUANG Bo;ZHANG Yi(Department of Immunology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Biotherapy Center of the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]中国医学科学院北京协和医学院免疫学系,北京100730 [2]郑州大学第一附属医院生物细胞治疗中心,郑州450052

出　　处：《科技导报》2023年第1期131-135,共5页Science & Technology Review

摘　　要：肿瘤免疫治疗已成为继手术、放疗、化疗之后的第四类肿瘤治疗方法,为当今国际研究的热点领域。在肿瘤免疫治疗新时代,以免疫检查点抑制剂、基因工程化修饰免疫细胞为代表的免疫疗法被认为具有广阔前景。概述了2022年肿瘤免疫治疗领域研究的热点及关键进展,包括嵌合抗原受体T细胞(CAR-T)在实体瘤治疗中的突破、维持记忆性T细胞生存和功能新机制的发现、改善肿瘤免疫抑制微环境提高免疫治疗疗效的深入探究以及瘤内微生物对抗肿瘤免疫反应的重要影响作用。Tumor immunotherapy has become the fourth type of tumor therapies after surgery,radiotherapy and chemotherapy,and a hot field of international research.Nowadays,we have entered the era of tumor immunotherapy,and immunotherapy represented by immune checkpoint inhibitors and genetically engineered immune cells is a promising therapy for cancers.This article summarizes the hot topics and key advances in cancer immunotherapy in 2022,including the breakthrough of chimeric antigen receptor T cells(CAR-T)in the treatment of solid tumors,the discovery of a new mechanism to maintain survival and function of memory T cells,the in-depth exploration of tumor immunosuppressive microenvironment to improve the efficacy of immunotherapy,and the important influence of intratumoral microbiota on immune responses against tumor.

关 键 词：肿瘤免疫 CAR-T细胞 记忆性T细胞 肿瘤免疫抑制微环境 瘤内微生物 

分 类 号：R730.3[医药卫生—肿瘤]